All In Biotech

NDA 022023 · Merck and CO INC

Emend

Fosaprepitant Dimeglumine · Intravenous

Novel

Last checked: Nov 21, 2026Latest source record: May 2, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jan 25, 2008

Approved uses

5

Original approval plus efficacy supplements

Registered trials

21

7 Phase 3, 0 recruiting

FAERS reports

19,186

17,114 serious, 3,248 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 20, 2026.

EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use ( 1 ) EMEND has not been studied for treatment of established nausea and vomiting. Limitations of Use EMEND has not been studied for the treatment of established nausea and vomiting.

Mechanism: Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EMEND · FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • EMEND · FOSAPREPITANT DIMEGLUMINE EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fosaprepitant Dimeglumine" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea2,321
  • fatigue2,054
  • pyrexia1,734
  • dyspnoea1,696
  • diarrhoea1,674
  • vomiting1,605
  • off label use1,489
  • alopecia1,412
  • rash1,330
  • hypersensitivity1,248
  • decreased appetite1,172
  • pruritus1,138

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004127
2005134
2006145
2007181
2008177
2009216
2010351
2011479
2012764
2013691
2014818
20151,057
20161,325
2017894
20181,376
20191,393
20201,186
20211,275
20221,170
20231,246
20241,848
20251,439
2026894

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Emend (Aprepitant)

2024 spending

$123K

Beneficiaries

15

49 claims

Per beneficiary

$8,193

$253.51 per unit

View as table
YearSpending
2020$54,636
2021$28,372
2022$76,475
2023$61,588
2024$122,902

Part D: Emend (Fosaprepitant Dimeglumine)

2024 spending

$7K

Beneficiaries

n/a

21 claims

Per beneficiary

n/a

$193.54 per unit

View as table
YearSpending
2020$48,894
2021$5,848
2022$2,438
2023$0
2024$7,355

Part B: Emend* (Fosaprepitant Dimeglumine*) · HCPCS J1453

2024 spending

$2.2M

Beneficiaries

21,354

104,356 claims

Per beneficiary

$103

2024 ASP limit $0.14 per unit

View as table
YearSpending
2020$51,275,458
2021$13,921,518
2022$2,823,785
2023$2,419,136
2024$2,206,841

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Merck and CO INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.